Breast cancer‐derived exosomes: Tumor progression and therapeutic agents. Issue 10 (26th March 2020)

• Record Type: Journal Article
• Authors: Jabbari, Nasrollah; Akbariazar, Elinaz; Feqhhi, Maryam; Rahbarghazi, Reza; Rezaie, Jafar
• Is Part Of: Journal of cellular physiology. Volume 235:Issue 10(2020:Oct.)
• Page Start: 6345
• Page End: 6356
• Publication Date: 2020-03-26
• Subjects: biomarker -- breast cancer -- exosome -- extracellular vesicles; Physiology -- Periodicals; Cell physiology -- Periodicals; 571.6
• DOI: 10.1002/jcp.29668
• Languages: English
• ISSNs: 0021-9541

Abstract

Abstract: Tumor cells secrete extracellular vesicles (EVs) for intercellular communication. EVs by transporting different proteins, nucleic acids, and lipids contribute to affect target cell function and fate. ‎EVs which originate directly from multivesicular bodies so‐called exosomes have dramatically fascinated the attention of researchers owing to their ‎pivotal roles in the tumorigenesis. Breast cancer, arising from milk‐producing cells, is the most identified cancer among women and has become the leading cause of cancer‐related death in women globally. Although different therapies are applied to eliminate breast tumor cells, however, the efficient therapy and survival rate of patients remain challenges. Growing evidence ‎shows exosomes from breast cancer cells contribute to proliferation, metastasis, angiogenesis, chemoresistance, and also radioresistance and, thus carcinogenesis. Additionally, these exosomes may serve as a cancer treatment tool because they are a good candidate for cancer diagnosis (as biomarker) and therapy (as drug‐carrier). Despite recent development in the biology of tumor‐derived exosomes, the detailed mechanism of tumorigenesis, and exosome‐based cancer‐therapy remain still indefinable. Here, we discuss the key function of breast cancer‐derived exosomes in tumorgenesis and shed light on the possible clinical application of these exosomes in breast cancer treatment. Abstract : Breast cancer‐derived exosomes contribute to maintain hemostasis and promote tumorigenesis. These exosomes may serve as a diagnostic/prognostic biomarker for breast cancer. Modification of exosomes could provide us to deliver therapeutic compounds to tumor cells more efficiently and specifically than other synthetic carriers.